Pharmacological blockade and genetic knock out of NOX2 have been shown to ameliorate diaphragm muscle weakness in models of DMD [21] and CHF [22], implicating a role for NOX2 derived ROS in muscle dysfunction. Here, CYBB is linked to Duchenne muscular dystrophy.